Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28206765 | 0.81 | ALDH1A1 (0.38) | ACHEKDM4ERAB9APOLBGAA | |
| SCHEMBL28084978 | 0.77 | P2RX3 (0.33) | KDM4ERAB9APOLBGAAALDH1A1 | |
| SCHEMBL9093356 | 0.76 | — | — | |
| SCHEMBL28178444 | 0.76 | LMNA (0.39) | KDM4ERAB9APOLBGAATSHR | |
| SCHEMBL7563047 | 0.72 | — | — | |
| SCHEMBL11250840 | 0.72 | ALDH1A1 (0.47) | BCHEACHEKDM4ERAB9AGAA | |
| SCHEMBL28069971 | 0.71 | MGAM (0.38) | KDM4ERAB9APOLBGAAALDH1A1 | |
| SCHEMBL27748687 | 0.71 | TSHR (0.35) | BCHEACHERAB9AGAATSHR | |
| SCHEMBL11346091 | 0.71 | — | — | |
| SCHEMBL8431048 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | claimed |
| EP-1799677-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | Ranbaxy Laboratories Limited (IN) | 2007-06-27 | — | — | EP | claimed |
| WO-2006038100-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-13 | — | — | WO | claimed |
| CN-112368289-B | C26-linked rapamycin analogues as MTOR inhibitors | 锐新医药公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-115916194-A | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
| EP-1799677-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | Ranbaxy Laboratories Limited (IN) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038100-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | CCNE1 1802/4885CDK2 1316/4885GSK3B 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.